Publications by authors named "Federica Repetto"
Introduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23. Current treatment options for HS are limited, as only adalimumab and secukinumab are approved for severe cases. Given the overlapping pathogenetic features between HS and psoriasis, anti-IL-17 and anti-IL-23 drugs could represent valuable treatments for the management of HS.
View Article and Find Full Text PDFReal-world data on the long-term effectiveness of the anti-IL17 agent secukinumab in treating moderate-to-severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 patients with moderate-severe HS received five weekly subcutaneous injections followed by maintenance doses every 4 weeks. Primary outcomes included HiSCR, IHS4 reduction, and DLQI measures assessed at 12-week intervals.
View Article and Find Full Text PDFArticle Synopsis
- Adalimumab is the sole biological drug approved for treating moderate to severe hidradenitis suppurativa, with reported adverse effects including paradoxical psoriasiform reactions.
- The paper aims to detail how often these reactions occur and their clinical characteristics in patients receiving adalimumab.
- It also shares real-life experiences in managing these reactions and discusses the potential use of other biologic agents for both hidradenitis suppurativa and psoriasis.
Article Synopsis
- * A study involving 37 patients over 12 months found no significant differences in clinical response when switching from the adalimumab originator to its biosimilar, though a high discontinuation rate of 43.2% raised concerns about patient compliance.
- * Pain at the injection site was a main reason for discontinuation (31.5%), but some patients (66.6%) benefited from switching back to the original adalimumab, highlighting the need for careful evaluation of the risks and